PATTI WICKLUND: Open Payments
NPI 1780373522 · OJAI, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,446 in 57 payments from 19 companies in 2025. Trend: 2023 $1,705 · 2024 $1,927 · 2025 $2,446
Food & beverage: $2,446
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $720 |
| Amgen Inc. | 5 | $235 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $157 |
| Novo Nordisk Inc | 2 | $149 |
| Ardelyx, Inc. | 2 | $138 |
| Neurocrine BioSciences, Inc. | 1 | $137 |
| Alkermes, Inc. | 1 | $129 |
| ACADIA Pharmaceuticals Inc | 1 | $121 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| ABBVIE INC. | 1 | $105 |
Products named: LOKELMA, KRYSTEXXA, FARXIGA, JARDIANCE, IBSRELA, INGREZZA, LYBALVI, BREZTRI.
Industry payments across CA — which companies pay providers there.
